221 related articles for article (PubMed ID: 20457354)
1. Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.
Sambade MJ; Kimple RJ; Camp JT; Peters E; Livasy CA; Sartor CI; Shields JM
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):575-81. PubMed ID: 20457354
[TBL] [Abstract][Full Text] [Related]
2. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.
Sambade MJ; Camp JT; Kimple RJ; Sartor CI; Shields JM
Radiother Oncol; 2009 Dec; 93(3):639-44. PubMed ID: 19853943
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
[TBL] [Abstract][Full Text] [Related]
5. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
7. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
Walters DM; Lindberg JM; Adair SJ; Newhook TE; Cowan CR; Stokes JB; Borgman CA; Stelow EB; Lowrey BT; Chopivsky ME; Gilmer TM; Parsons JT; Bauer TW
Neoplasia; 2013 Feb; 15(2):143-55. PubMed ID: 23441129
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
Tsai YC; Ho PY; Tzen KY; Tuan TF; Liu WL; Cheng AL; Pu YS; Cheng JC
Mol Cancer Ther; 2015 Mar; 14(3):810-20. PubMed ID: 25589492
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
[TBL] [Abstract][Full Text] [Related]
11. A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer.
Lin CY; Chao A; Wang TH; Hsueh S; Lee YS; Wu TI; Chao AS; Huang HJ; Chou HH; Chang TC; Lai CH
J Mol Med (Berl); 2014 Sep; 92(9):969-81. PubMed ID: 24820961
[TBL] [Abstract][Full Text] [Related]
12. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
[TBL] [Abstract][Full Text] [Related]
13. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
Konecny GE; Venkatesan N; Yang G; Dering J; Ginther C; Finn R; Rahmeh M; Fejzo MS; Toft D; Jiang SW; Slamon DJ; Podratz KC
Br J Cancer; 2008 Mar; 98(6):1076-84. PubMed ID: 18334972
[TBL] [Abstract][Full Text] [Related]
14. Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.
Kimple RJ; Horton JK; Livasy CA; Shields JM; Lawrence JA; Chiu WM; Ivanova A; Ollila DW; Carey LA; Halle JS; Sartor CI; Dees EC
Oncologist; 2012; 17(12):1496-503. PubMed ID: 23006498
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
Mu Y; Sun D
Med Sci Monit; 2018 Aug; 24():5811-5819. PubMed ID: 30125265
[TBL] [Abstract][Full Text] [Related]
16. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
17. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
Kim HP; Yoon YK; Kim JW; Han SW; Hur HS; Park J; Lee JH; Oh DY; Im SA; Bang YJ; Kim TY
PLoS One; 2009 Jun; 4(6):e5933. PubMed ID: 19529774
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.
Jabbarzadeh Kaboli P; Leong MP; Ismail P; Ling KH
Pharmacol Rep; 2019 Feb; 71(1):13-23. PubMed ID: 30343043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
